静脉注射免疫球蛋白可能会降低视神经脊髓炎的复发频率。
Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.
作者信息
Viswanathan Shanthi, Wong Anna H Y, Quek Amy M L, Yuki Nobuhiro
机构信息
Department of Neurology, Kuala Lumpur Hospital, Malaysia.
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
出版信息
J Neuroimmunol. 2015 May 15;282:92-6. doi: 10.1016/j.jneuroim.2015.03.021. Epub 2015 Mar 28.
OBJECTIVES
To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).
METHODS
Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded.
RESULTS
Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years.
CONCLUSION
IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.
目的
评估静脉注射免疫球蛋白（IVIG）在预防视神经脊髓炎（NMO）及其谱系障碍（NMOSD）患者复发中的应用。
方法
回顾性确定6例接受IVIG诱导剂量治疗，随后每2至3个月输注一次的NMO/NMOSD患者。记录IVIG治疗前后的年化复发率（ARR）和扩展残疾状态量表（EDSS）。
结果
复发中位数和ARR中位数分别从8.0显著降至1.0和从0.75降至0.15（p<0.05）。EDSS中位数6.5保持不变。中位治疗持续时间为4.0年。
结论
IVIG可用于降低NMO/NMOSD患者的复发频率。
Zotero 插件